A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

NCT07487311 · clinicaltrials.gov ↗

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Inflamatory Bowel Disease

Interventions

DRUG: guselkumab (GUS), JAK inhibitors (such as upadacitinib/tofacitinib)

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University